disease state e g causing regression of the disease state until a desired endpoint is reached treating also includes the amelioration of a symptom of a disease e g lessen the pain or discomfort wherein such amelioration may or may not be directly affecting the disease e g cause transmission expression etc u201c therapeutically effective amount u201d includes an amount of a compound of the present invention that is effective when administered alone or in combination to treat the desired condition or disorder u201c therapeutically effective amount u201d includes an amount of the combination of compounds claimed that is effective to treat the desired condition or disorder the combination of compounds is preferably a synergistic combination synergy as described for example by chou and talalay adv enzyme regul 1984 22 27 55 occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent in general a synergistic effect is most clearly demonstrated at sub optimal concentrations of the compounds synergy can be in terms of lower cytotoxicity increased antiviral effect or some other beneficial effect of the combination compared with the individual components u201c pharmaceutically acceptable salts u201d refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof examples of pharmaceutically acceptable salts include but are not limited to mineral or organic acid salts of the basic residues the pharmaceutically acceptable salts include the conventional quaternary ammonium salts of the parent compound formed for example from non toxic inorganic or organic acids for example such conventional non toxic salts include but are not limited to those derived from inorganic and organic acids selected from 1 2 ethanedisulfonic 2 acetoxybenzoic 2 hydroxyethanesulfonic acetic ascorbic.